Could GLP-1 weight-loss medications like Ozempic become the 'everything drug'?

Medical experts discuss whether GLP-1 medications, including Mounjaro and Zepbound, could become comprehensive treatments for multiple health conditions. Read More

New tariffs could raise prices of Ozempic, Wegovy

(NEXSTAR) – A trade deal between the U.S. and the European Union is expected to impose a 15% tax on pretty much all goods imported from Europe, from fancy French wines to sleek German cars and ... Read More

Nearly 17 Million Young Americans Could Benefit From Ozempic-like Drugs

Despite this, one in five young adults who meet the criteria for the drugs are uninsured and one-third denied having a routine place for healthcare. Read More

The Heavy Cost of Using Weight-Loss Drugs to Get Skinny

GLP-1 medications have taken America by storm, moving beyond clinical tools and becoming status symbols. Once accessible to only the wealthy and well-connected, they are now prescribed in clinics ... Read More

The Ozempic effect: From shopping baskets to dips in Danish GDP

Denmark sliced its 2025 economic growth forecast in half recently after a cool-down at Novo Nordisk, the maker of diabetes drugs Ozempic and Wegovy, which have become popular among those wanting to ... Read More

Ozempic teeth: Dentists warn of new GLP-1 side effect

Patients using Ozempic and other GLP-1 drugs are reporting a complication not listed among the drug’s most common side effects. We’re not talking about “Ozempic babies,” but that’s also a thing. Read More

Novo Nordisk, maker of Wegovy and Ozempic, to cut 9,000 jobs

The Danish pharmaceutical company said it would cut 9,000 jobs, 5,000 of them in Denmark, in order to strengthen the company's focus on growth opportunities in obesity and diabetes medications. Read More

Could GLP-1 weight-loss medications like Ozempic become the 'everything drug'?

GLP-1 agonists — including semaglutides like Ozempic and Wegovy and tirzepatides like Mounjaro and Zepbound — were originally intended to treat type 2 diabetes and obesity. But in recent months, ... Read More